MOTS-c Peptide Research: Mitochondrial Signaling and Evidence
MOTS-c is a mitochondrial-derived peptide studied in cellular stress, metabolic signaling, exercise physiology and aging-related models. This guide separates experimental observations from unproven human claims.
What is MOTS-c?
MOTS-c is a 16-amino-acid mitochondrial-derived peptide. The reported human sequence is MRWQEMGYIFYPRKLR. Its free-base molecular formula is C101H152N28O22S2, with molecular weight of approximately 2174.6 g/mol. PubChem provides the sequence and chemical identifiers.
MRWQEMGYIFYPRKLRThe name is derived from “mitochondrial open-reading-frame of the 12S rRNA-c.” Correct identity matters: sequence, salt form, impurities and degradation products can change what is being evaluated. Researchers should verify lot-specific identity rather than relying on a product name alone.
A mitochondrially encoded signaling peptide
The original 2015 Cell Metabolism paper described MOTS-c as a peptide encoded within mitochondrial 12S rRNA and examined its role in metabolic regulation. Researchers used cultured-cell experiments and mouse models to investigate glucose-related and metabolic responses, connecting several observations with AMPK-associated signaling. Read the original paper.
This work helped establish MOTS-c as a candidate signaling molecule connecting mitochondrial information with cellular metabolic responses. It did not establish that administered synthetic MOTS-c safely produces beneficial outcomes in people.
AMPK, metabolic stress and nuclear translocation
A 2018 study examined MOTS-c during metabolic stress. Investigators reported AMPK-dependent movement of MOTS-c into the nucleus, interaction with stress-response signaling involving NRF2, and association with promoter regions containing antioxidant-response-element motifs. The experiments linked those observations with changes in stress-response gene expression and cellular survival. Read the original Cell Metabolism study.
This proposed a mechanism through which a mitochondrially encoded peptide could participate in nuclear gene regulation. It is a mechanistic model, not proof of a clinical outcome. Mentioning AMPK or NRF2 does not establish that MOTS-c treats metabolic disease, reverses aging or improves human performance.
Preclinical metabolic-homeostasis models
The 2015 research reported MOTS-c-associated changes in cultured cells and mouse metabolic models, including animals exposed to a high-fat diet. These experiments are often summarized online as “metabolic benefits.” A scientifically accurate summary retains the model: investigators observed specific responses in cells and mice under defined conditions.
Preclinical results do not establish that the same exposure, distribution, duration or outcome occurs in humans. Animal strain, diet, age, timing and assay selection can all influence the result; reproducibility and independent confirmation remain important.
Exercise and age-related research
A 2021 Nature Communications paper investigated MOTS-c in age- and exercise-related contexts using substantial mouse experimentation and observations of endogenous MOTS-c in human participants. Review the original study.
The human component did not establish the safety or effectiveness of administering synthetic MOTS-c. It examined naturally occurring peptide responses associated with exercise. A separate human physiology study likewise measured endogenous mitochondrial-derived peptides after acute endurance and resistance exercise. That observational study is indexed by PubMed.
Detecting a naturally produced molecule during exercise does not demonstrate that an externally supplied version reproduces exercise, improves performance or has a favorable risk-benefit profile.
What human studies do—and do not—show
Human research has helped examine endogenous MOTS-c levels and exercise physiology. It has not established therapeutic effectiveness for an administered MOTS-c product.
FDA’s 2026 evaluation reported no clinical studies establishing safety or effectiveness of MOTS-c drug substances in humans and no adequate human exposure data for MOTS-c drug products at the time of review. FDA also identified uncertainty involving peptide impurities, aggregation, immunogenicity and product characterization. Read the agency’s MOTS-c evidence review.
A newly registered trial does not change the evidence category until results are completed, reported and critically evaluated. Registration is a research milestone, not proof of efficacy. MOTS-c is not an FDA-approved drug.
Evaluating MOTS-c research material
- Sequence and identity: Does the material match
MRWQEMGYIFYPRKLR? - Chemical form: Does the stated formula describe the free peptide or a disclosed salt form?
- Chromatographic purity: What did the method resolve, and how was purity calculated?
- Quantitative content: How much peptide was measured in the vial?
- Endotoxin: Is there a lot-specific result with method and reporting limit?
- Lot traceability: Do the vial and report identifiers match?
Purity alone does not establish identity, quantitative content, sterility, safety or experimental performance. Review the peptide COA verification guide before evaluating a lot.
Qualified laboratories can review the MOTS-c research listing and current lot documentation. BulkGLP’s Verified Quality page explains the broader quality-documentation approach; the product record remains the controlling source for a specific MOTS-c lot.
Frequently asked questions
What does MOTS-c stand for?
MOTS-c refers to the mitochondrial open-reading-frame of the 12S rRNA-c.
Is MOTS-c encoded by mitochondrial DNA?
The published literature describes MOTS-c as a 16-amino-acid peptide encoded by a short open reading frame within mitochondrial 12S rRNA.
Which pathways are being studied?
Research has examined AMPK-associated energy signaling, metabolic-stress-related nuclear translocation, NRF2 interaction and antioxidant-response-element-associated gene regulation.
Do exercise studies prove that synthetic MOTS-c works in humans?
No. Human exercise studies primarily measured endogenous MOTS-c and did not establish safety or effectiveness of an administered product.
Is MOTS-c approved for human use?
No. MOTS-c is not an FDA-approved drug.
Primary references
- PubChem: MOTS-c compound record
- Original 2015 MOTS-c paper
- MOTS-c nuclear translocation during metabolic stress
- Exercise and age-related MOTS-c research
- FDA 2026 MOTS-c evidence evaluation